Company intelligence / Profile preview

Lybra Bio

Cambridge, Massachusetts, United Stateslinkedin.com ↗

Ownership: Private
Development stage: Preclinical

Overview

Lybra Bio is developing a platform that combines clinically validated cytokines with an advanced microneedle patch to restore immune equilibrium in patients with autoimmune skin diseases. The approach aims for superior efficacy and patient compliance while minimizing systemic side effects. No clinical results have been reported as of May 2025; the company appears to be preclinical and was recently selected for the MassBioDrive accelerator program Fall 2024 cohort.

Therapeutic areas: Immunology
Modalities: CytokinesMicroneedle patch drug delivery system
Industry: Biotech

Partnerships

MassBioDrive accelerator program participant Fall 2024 cohort

Beyond the preview

Go deeper on Lybra Bio.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Lybra Bio.

Explore the full profile